Call 413.540.1234 to
schedule an appointment
CONCERN/EAP: 413.534.2625
Billing questions? Call: 413.540.1212
CRISIS: 413.733.6661

Depression: Depression & Related Conditions
Resources
Basic Information
Introduction and Types of Depressive DisordersRelated Disorders / ConditionsHistorical and Current UnderstandingsBiology, Psychology and SociologyTreatment - Medication and PsychotherapyAlternative Medicine and Self-Help ResourcesSpecial IssuesReferences
More InformationTestsLatest News
Is Depression During Pregnancy on the Rise?Know the Signs of Postpartum DepressionAre Your Meds Making You Depressed?Depression, Money Woes Higher in Heart Patients With Job LossSnubbed on Social Media? Your Depression Risk May RiseNever Ignore DepressionStudy Affirms What Many Know: Antidepressants May Lead to Weight GainECT Effective for Treatment-Resistant DepressionRates of Major Depression Up Among U.S. Insured, Esp. YouthResistance Exercise May Reduce Depressive Symptoms in AdultsDepression Striking More Young People Than EverDepression May Dampen MemoryCould Mom-to-Be's Antidepressants Have an Upside for Baby's Brain?Exercise Your Blues AwayGrip Strength Indicative of Cognition in Major DepressionKetamine Nasal Spray Shows Promise Against Depression, SuicideTelltale Clues That Your Child Is DepressedPrenatal Exposure to SSRI Tied to Fetal Brain DevelopmentDepressive Symptoms Tied to Diabetes Self-ManagementAbandoning Your Workouts May Bring on the BluesMany Grad Students Struggle With Anxiety, DepressionRelapse in Major Depression Linked to Brain Cortical ChangesIL-6 Levels Predict Response to ECT in Depressive Disorder1 in 20 Younger Women Suffers Major DepressionHeart-Healthy 'DASH' Diet May Also Help Lower Depression RiskGuidelines Updated for Managing and ID'ing Adolescent Depression21 Reviewed Antidepressants Top Placebo for Major DepressionAntidepressants Do Work, Some Better Than Others: StudyTreatment Initiation for Depression Low in Primary CareDuring 2013 to 2016, 8.1 Percent of U.S. Adults Had DepressionDepression Common in U.S., Women Hit HardestNo Proof At-Home 'Cranial Stimulation' Eases DepressionAcne Linked to Increased Risk of Major Depressive DisorderMany With Depression Delay, Avoid TreatmentPostnatal Depression Tied to Child Behavioral ProblemsTalk Therapy May Be Worth It for Teen DepressionCognitive Behavioral Therapy Cost-Effective in Depressed TeensWomen Seem More Prone to Winter BluesTransdermal Estradiol May Help Prevent Depressive SymptomsHormone Therapy May Ease Depression Linked to MenopauseEsketamine Safe, Effective for Treatment-Resistant DepressionDermatologists Often Undervalue Depression, Anxiety in PatientsFeeling Sad? Here's How to Beat the Holiday BluesImpaired White Matter Integrity for Depression in Parkinson'sHealth Tip: Fight Seasonal Affective DisorderNetwork Density Not Linked to Response in Teen DepressionSimple ECG May Help Distinguish MDD From Bipolar DepressionTreatment Trajectories Vary for Children With DepressionIf Dad Has Depression, Kids Might Develop It, TooPsychedelic Amazonian Drug Might Ease Symptoms of Depression, Alcoholism
Questions and AnswersLinksBook Reviews
Related Topics

Anxiety Disorders
Bipolar Disorder
Suicide
Addictions: Alcohol and Substance Abuse
Pain Management

Transdermal Estradiol May Help Prevent Depressive Symptoms


HealthDay News
Updated: Jan 11th 2018

new article illustration

THURSDAY, Jan. 11, 2018 (HealthDay News) -- Transdermal estradiol (TE) plus intermittent micronized progesterone (IMP) can prevent clinically significant depressive symptoms among euthymic perimenopausal and early postmenopausal women, according to a study published online Jan. 10 in JAMA Psychiatry.

Jennifer L. Gordon, Ph.D., from the University of Regina in Canada, and colleagues conducted a randomized trial involving euthymic perimenopausal and early postmenopausal women aged 45 to 60 years. Participants were randomized to 12 months of TE or transdermal placebo. Women receiving TE also received micronized progesterone every three months; women receiving placebo were given identical placebo pills.

The researchers found that, compared with women receiving TE+IMP, those assigned to placebo were more likely to score at least 16 on the Center for Epidemiological Studies-Depression Scale (CES-D), indicating clinically significant depressive symptoms, at least once during the intervention phase (32.3 versus 17.3 percent; odds ratio, 2.5); they also had a higher mean CES-D score across the intervention period. The effect of treatment was moderated by baseline reproductive stage, with the mood benefits of TE+IMP versus placebo seen among women in the early menopause transition but not those in the late menopause transition or among postmenopausal women.

"Twelve months of TE+IMP were more effective than placebo in preventing the development of clinically significant depressive symptoms among initially euthymic perimenopausal and early postmenopausal women," the authors write.

Abstract/Full Text
Editorial